Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analysed the earning revision of component stocks of STAR50 in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on SUPCON TECHNOLOGY, SHENGYI ELECTRONICS, TRANSSION, TRINA SOLAR, CAMBRICON TECHNOLOGIES, Trina Solar, Shengyi Electronics, Cambricon Technologies, Transsion, Supcon Technology.</li>
</ul>


We analysed the earning revision of component stocks of STAR50 in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on SUPCON TECHNOLOGY, SHENGYI ELECTRONICS, TRANSSION, TRINA SOLAR, CAMBRICON TECHNOLOGIES, Trina Solar, Shengyi Electronics, Cambricon Technologies, Transsion, Supcon Technology.


STAR50 Index Earning Revision (Oct): SUPCON TECHNOLOGY, SHENGYI ELECTRONICS, TRANSSION, TRINA SOLAR

Equity Capital Markets

Sichuan Biokin Pharmaceutical Co Ltd / Equity Capital Markets

Sichuan Biokin Pharmaceutical Co Ltd (SBP12 HK)

<ul>
<li>Sichuan Biokin is looking to raise up to USD 500 million from an A-H listing. The sponsors are GS, JPM, and CITIC.</li>
<li>Sichuan Biokin recently published its post-hearing prospectus. The company also released financial results for 3Q 2025.</li>
<li>We think the company has progressed well in its core asset and has reported encouraging clinical data since the beginning of the year.</li>
</ul>


Sichuan Biokin is looking to raise up to USD 500 million from an A-H listing. The sponsors are GS, JPM, and CITIC.
Sichuan Biokin recently published its post-hearing prospectus. The company also released financial results for 3Q 2025.
We think the company has progressed well in its core asset and has reported encouraging clinical data since the beginning of the year.


Sichuan Biokin A/H Listing: Milestone Payment and New Clinical Data

<ul>
<li>We analysed the earning revision of component stocks of CSI 300 in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on Wuxi Apptec, Eoptolink Technology, Ping An Insurance, Muyuan Foods, China Vanke, Jinko Solar, Xinjiang Daqo.</li>
</ul>


We analysed the earning revision of component stocks of CSI 300 in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on Wuxi Apptec, Eoptolink Technology, Ping An Insurance, Muyuan Foods, China Vanke, Jinko Solar, Xinjiang Daqo.


CSI 300 Index Earning Revision (Jul): Wuxi Apptec, Eoptolink Technology, Ping An Insurance

<ul>
<li>We analysed the earning revision of component stocks of STAR50 in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on Xinjiang Daqo, Hwatsing Technology, Jinko Solar, Transsion, Montage Technology.</li>
</ul>


We analysed the earning revision of component stocks of STAR50 in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on Xinjiang Daqo, Hwatsing Technology, Jinko Solar, Transsion, Montage Technology.


STAR50 Index Earning Revision (Jul): Xinjiang Daqo, Hwatsing Technology, Jinko Solar, Transsion

<ul>
<li>We analysed the earning revision of component stocks of STAR50 in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on Bestechnic (Shanghai), Csi Solar, Biwin Storage Technology, Transsion, Xinjiang Daqo.</li>
</ul>


We analysed the earning revision of component stocks of STAR50 in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on Bestechnic (Shanghai), Csi Solar, Biwin Storage Technology, Transsion, Xinjiang Daqo.


STAR50 Index Earning Revision (Jun): Bestechnic, Csi Solar, Biwin Storage Technology

China

Sichuan Biokin Pharmaceutical Co.,Ltd. operates as a pharmaceutical company. The Company produces children's medicine, cardiovascular drugs, anesthetics, chronic disease drugs, and more. Sichuan Biokin Pharmaceutical conducts businesses worldwide.

Sichuan Biokin Pharmaceutical (688506 CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sichuan Biokin Pharmaceutical (688506 CH)

STAR50 Index Earning Revision (Oct): SUPCON TECHNOLOGY, SHENGYI ELECTRONICS, TRANSSION, TRINA SOLAR

We analyzed STAR50's consensus for Oct 2025 and highlighted changes of EPS in SUPCON TECHNOLOGY (688777 CH), SHENGYI ELECTRONICS (688183 CH),...

Ke Yan, CFA, FRM

Sichuan Biokin A/H Listing: Milestone Payment and New Clinical Data

Sichuan Biokin aims to raise $500 million through A-H listing with backing from GS, JPM, and CITIC. Recent development for the company is mostly...

Ke Yan, CFA, FRM

CSI 300 Index Earning Revision (Jul): Wuxi Apptec, Eoptolink Technology, Ping An Insurance

We analyzed CSI 300's consensus for Jul 2025 and highlighted changes of EPS in Wuxi Apptec, Eoptolink Technology, Ping An Insurance, Muyuan Foods,...

Ke Yan, CFA, FRM

STAR50 Index Earning Revision (Jul): Xinjiang Daqo, Hwatsing Technology, Jinko Solar, Transsion

We analyzed STAR50's consensus for Jul 2025 and highlighted changes of EPS in Xinjiang Daqo, Hwatsing Technology, Jinko Solar, Transsion, Montage...

Ke Yan, CFA, FRM

STAR50 Index Earning Revision (Jun): Bestechnic, Csi Solar, Biwin Storage Technology

We analyzed STAR50's consensus for Jun 2025 and highlighted changes of EPS in Bestechnic (Shanghai), Csi Solar, Biwin Storage Technology,...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

STAR50 Index Earning Revision (Oct): SUPCON TECHNOLOGY, SHENGYI ELECTRONICS, TRANSSION, TRINA SOLAR

We analyzed STAR50's consensus for Oct 2025 and highlighted changes of EPS in SUPCON TECHNOLOGY (688777 CH), SHENGYI ELECTRONICS (688183 CH),...

Ke Yan, CFA, FRM

Sichuan Biokin A/H Listing: Milestone Payment and New Clinical Data

​Sichuan Biokin aims to raise $500 million through A-H listing with backing from GS, JPM, and CITIC. Recent development for the company is mostly...

Ke Yan, CFA, FRM

CSI 300 Index Earning Revision (Jul): Wuxi Apptec, Eoptolink Technology, Ping An Insurance

We analyzed CSI 300's consensus for Jul 2025 and highlighted changes of EPS in Wuxi Apptec, Eoptolink Technology, Ping An Insurance, Muyuan Foods,...

Ke Yan, CFA, FRM

STAR50 Index Earning Revision (Jul): Xinjiang Daqo, Hwatsing Technology, Jinko Solar, Transsion

We analyzed STAR50's consensus for Jul 2025 and highlighted changes of EPS in Xinjiang Daqo, Hwatsing Technology, Jinko Solar, Transsion, Montage...

Ke Yan, CFA, FRM

STAR50 Index Earning Revision (Jun): Bestechnic, Csi Solar, Biwin Storage Technology

We analyzed STAR50's consensus for Jun 2025 and highlighted changes of EPS in Bestechnic (Shanghai), Csi Solar, Biwin Storage Technology,...

Ke Yan, CFA, FRM

Sichuan Biokin aims to raise $500 million through A-H listing with backing from GS, JPM, and CITIC. Recent development for the company is mostly...